Glucagon-like peptide-1 news

The investment boosts GLP-1 production, creates 500 construction jobs, and enhances Ireland's role in global supply outside the US. Completion expected by 2028.

The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.

UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.

The new facility will create 2,800 jobs, produce weight-loss medicines, and boost the local economy with advanced technologies and partnerships in education and workforce development.